Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma (NAMS) with an Overweight rating and $42 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential Highlighted
- Strong Investment Potential for NewAmsterdam Pharma’s Obicetrapib Due to Cardiovascular and Metabolic Benefits
- Buy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue Growth
- Strong Financial Position and Promising Cardiovascular Developments Propel NewAmsterdam Pharma’s Growth Potential
- NewAmsterdam Pharma Reports Q1 2025 Financial Results